PE20211662A1 - Receptores que ofrecen coestimulacion especifica para terapia adoptiva de celulas - Google Patents
Receptores que ofrecen coestimulacion especifica para terapia adoptiva de celulasInfo
- Publication number
- PE20211662A1 PE20211662A1 PE2021001181A PE2021001181A PE20211662A1 PE 20211662 A1 PE20211662 A1 PE 20211662A1 PE 2021001181 A PE2021001181 A PE 2021001181A PE 2021001181 A PE2021001181 A PE 2021001181A PE 20211662 A1 PE20211662 A1 PE 20211662A1
- Authority
- PE
- Peru
- Prior art keywords
- costar
- cell therapy
- receptors
- stimulation
- adoptive cell
- Prior art date
Links
- 238000011467 adoptive cell therapy Methods 0.000 title abstract 3
- 102000006306 Antigen Receptors Human genes 0.000 abstract 1
- 108010083359 Antigen Receptors Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000000139 costimulatory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invencion se refiere a una celula que comprende un receptor de antigeno coestimulador quimerico (CoStAR) util en la terapia adoptiva de celulas (ACT). El CoStAR puede actuar como modulador de la actividad celular mejorando las respuestas a antigenos definidos. La presente invencion tambien proporciona proteinas CoStAR, acidos nucleicos que codifican el CoStAR y usos terapeuticos de los mismos
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1900858.0A GB201900858D0 (en) | 2019-01-22 | 2019-01-22 | Receptors providing targeted costimulation for adoptive cell therapy |
US201962951770P | 2019-12-20 | 2019-12-20 | |
PCT/GB2020/050120 WO2020152451A1 (en) | 2019-01-22 | 2020-01-20 | Receptors providing targeted costimulation for adoptive cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211662A1 true PE20211662A1 (es) | 2021-08-26 |
Family
ID=65655981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001181A PE20211662A1 (es) | 2019-01-22 | 2020-01-20 | Receptores que ofrecen coestimulacion especifica para terapia adoptiva de celulas |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220160760A1 (es) |
EP (1) | EP3914611A1 (es) |
JP (1) | JP2022518240A (es) |
KR (1) | KR20210118426A (es) |
CN (1) | CN113423726A (es) |
AU (1) | AU2020211375A1 (es) |
BR (1) | BR112021014360A2 (es) |
CA (1) | CA3126431A1 (es) |
CL (1) | CL2021001746A1 (es) |
CO (1) | CO2021009302A2 (es) |
CR (1) | CR20210398A (es) |
EA (1) | EA202192024A1 (es) |
EC (1) | ECSP21052180A (es) |
GB (1) | GB201900858D0 (es) |
IL (1) | IL284422A (es) |
MX (1) | MX2021008657A (es) |
PE (1) | PE20211662A1 (es) |
SG (1) | SG11202106787SA (es) |
WO (1) | WO2020152451A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ (ユーケイ) リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
CN116348485A (zh) * | 2020-07-17 | 2023-06-27 | 英研生物(英国)有限公司 | 提供用于过继性细胞疗法的靶向共刺激的受体 |
US20230277670A1 (en) * | 2020-07-17 | 2023-09-07 | John Bridgeman | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
CA3205464A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
JP2024500748A (ja) | 2020-12-18 | 2024-01-10 | インスティル バイオ (ユーケイ) リミテッド | 腫瘍浸潤リンパ球の処理 |
TW202305360A (zh) | 2021-03-25 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 用於t細胞共培養效力測定及配合細胞療法產品使用的方法及組合物 |
EP4355340A1 (en) * | 2021-06-16 | 2024-04-24 | Instil Bio, Inc. | Receptors providing targeted costimulation for adoptive cell therapy |
WO2023288278A1 (en) * | 2021-07-16 | 2023-01-19 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
US20240058447A1 (en) * | 2022-05-25 | 2024-02-22 | Instil Bio (Uk) Limited | Use of fusion constructs for il-2 independent t cell therapy |
WO2024030758A1 (en) * | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
EP1257632B1 (en) | 2000-02-24 | 2007-09-12 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
EP2295588B1 (en) | 2004-05-27 | 2018-03-07 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses thefor |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
WO2015179801A1 (en) * | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
SG10201908203SA (en) * | 2015-03-05 | 2019-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins And Uses Thereof |
GB201513540D0 (en) * | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
JP2021514631A (ja) * | 2018-02-26 | 2021-06-17 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための組成物および方法 |
CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
GB201910605D0 (en) * | 2019-07-24 | 2019-09-04 | Immetacyte Ltd | Tumour infltracting lymphocyte therapy amd uses thereo |
JP2022547416A (ja) * | 2019-08-28 | 2022-11-14 | キングス・カレッジ・ロンドン | B細胞標的化並列CAR(pCAR)治療的薬剤 |
WO2022225981A2 (en) * | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
-
2019
- 2019-01-22 GB GBGB1900858.0A patent/GB201900858D0/en not_active Ceased
-
2020
- 2020-01-20 CN CN202080010395.7A patent/CN113423726A/zh active Pending
- 2020-01-20 EA EA202192024A patent/EA202192024A1/ru unknown
- 2020-01-20 AU AU2020211375A patent/AU2020211375A1/en active Pending
- 2020-01-20 KR KR1020217025923A patent/KR20210118426A/ko unknown
- 2020-01-20 EP EP20701871.4A patent/EP3914611A1/en active Pending
- 2020-01-20 SG SG11202106787SA patent/SG11202106787SA/en unknown
- 2020-01-20 CR CR20210398A patent/CR20210398A/es unknown
- 2020-01-20 BR BR112021014360-2A patent/BR112021014360A2/pt not_active Application Discontinuation
- 2020-01-20 JP JP2021541684A patent/JP2022518240A/ja active Pending
- 2020-01-20 CA CA3126431A patent/CA3126431A1/en active Pending
- 2020-01-20 MX MX2021008657A patent/MX2021008657A/es unknown
- 2020-01-20 PE PE2021001181A patent/PE20211662A1/es unknown
- 2020-01-20 WO PCT/GB2020/050120 patent/WO2020152451A1/en unknown
-
2021
- 2021-06-27 IL IL284422A patent/IL284422A/en unknown
- 2021-06-29 US US17/361,621 patent/US20220160760A1/en active Pending
- 2021-06-30 CL CL2021001746A patent/CL2021001746A1/es unknown
- 2021-07-15 CO CONC2021/0009302A patent/CO2021009302A2/es unknown
- 2021-07-15 EC ECSENADI202152180A patent/ECSP21052180A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA202192024A1 (ru) | 2021-12-20 |
MX2021008657A (es) | 2021-08-19 |
CL2021001746A1 (es) | 2022-02-11 |
US20220160760A1 (en) | 2022-05-26 |
GB201900858D0 (en) | 2019-03-13 |
KR20210118426A (ko) | 2021-09-30 |
BR112021014360A2 (pt) | 2021-10-05 |
CA3126431A1 (en) | 2020-07-30 |
CO2021009302A2 (es) | 2021-08-09 |
WO2020152451A1 (en) | 2020-07-30 |
AU2020211375A1 (en) | 2021-08-26 |
ECSP21052180A (es) | 2021-08-31 |
CR20210398A (es) | 2021-12-06 |
EP3914611A1 (en) | 2021-12-01 |
IL284422A (en) | 2021-08-31 |
SG11202106787SA (en) | 2021-07-29 |
CN113423726A (zh) | 2021-09-21 |
JP2022518240A (ja) | 2022-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211662A1 (es) | Receptores que ofrecen coestimulacion especifica para terapia adoptiva de celulas | |
AR123004A1 (es) | Receptores que proveen coestimulación direccionada útil para terapia celular adoptiva | |
BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
CO2020001491A2 (es) | Molécula de polipéptido con especificidad dual mejorada | |
CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
PE20200485A1 (es) | Proteinas de union a antigenos trem2 y usos de estas | |
CL2021001986A1 (es) | Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1). | |
CL2022001375A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y usos de los mismos | |
CU20170023A7 (es) | Anticuerpos y receptores de antígeno quiméricos específicos para cd19 | |
EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
CL2021001628A1 (es) | Anticuerpo humanizado anti-pd-1 humana | |
PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
AR092050A1 (es) | Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
AR123005A1 (es) | Moléculas quiméricas que proveen coestimulación direccionada útil para terapia celular adoptiva | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
EA202190573A1 (ru) | Композиции и способы перепрограммирования tcr с применением гибридных белков | |
CO2021015544A2 (es) | Moléculas de unión a cd19 y usos de las mismas | |
ECSP22041860A (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
AR115695A1 (es) | Moléculas proteicas multifuncionales que comprenden decorina y uso de estas | |
AR098950A1 (es) | Anticuerpo contra bdca-2 humano | |
BR112022013940A2 (pt) | Receptores de antígenos quiméricos para eliminação de amiloides | |
CO2020015052A2 (es) | Anticuerpos anti-cd63, conjugados y usos de estos | |
BR112022006782A2 (pt) | Receptores de citocina quiméricos | |
UY35154A (es) | ANTICUERPOS MONOCLONALES CONTRA UNA PROTEÍNA ACTIVADA C (aPC) |